Longevity & AgingNew LRRK2 Inhibitor Shows Early Promise Against Alzheimer's in High-Risk Gene Carriers
Halia Therapeutics has shared early-stage data on HT-4253, a drug designed to block a brain inflammation pathway linked to Alzheimer's disease. In lab studies, the drug reduced harmful inflammation in brain immune cells, lowered tau protein buildup in neurons, and restored cellular cleanup functions. These are all processes that go wrong in Alzheimer's. Building on a Phase 1 safety trial, the company now plans a 48-week Phase 2a study targeting people who carry the APOE4 gene — the strongest known genetic risk factor for Alzheimer's — but who show no symptoms yet. Participants will be identified using population-scale genomics in the UAE and screened with a blood test to detect early amyloid buildup, a hallmark of the disease.
